Related Experiment Video

Updated: Aug 16, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Epidermal growth factor receptor inhibitors in lung cancer therapy

Janessa J Laskin1, Alan B Sandler

  • 1Division of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada. jlaskin@bccancer.bc.ca

Seminars in Respiratory and Critical Care Medicine
|August 10, 2005
PubMed

Insights

Targeted cancer therapy, specifically epidermal growth factor receptor (EGFR) inhibitors, offers a new approach to treating lung cancer. These agents show promising antitumor effects and improve quality of life with manageable side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer biology knowledge has advanced targeted cancer therapy.
  • Lung cancer mortality remains a challenge.
  • Epidermal growth factor receptor (EGFR) inhibitors are a novel therapeutic option.

Purpose of the Study:

  • To review the rationale, utility, toxicity, and strategy of EGFR-targeted therapy in lung cancer.

Main Methods:

  • Literature review of EGFR inhibitor studies.
  • Analysis of clinical trial data.
  • Evaluation of treatment outcomes and side effects.

Main Results:

  • EGFR inhibitors demonstrate significant antitumor activity.
  • These therapies provide quality-of-life benefits.
  • Toxicity profiles are generally acceptable.

Conclusions:

  • EGFR inhibitors represent a valuable addition to lung cancer treatment.
  • Understanding their profile is crucial for effective integration into multimodality therapy.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: